정밀 종양학 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the precision oncology market size was valued at USD 115.51 billion in 2025 and is estimated to grow from USD 127.68 billion in 2026 to reach USD 201.27 billion by 2031, at a CAGR of 9.53% during the forecast period (2026-2031).

This report Segments the Industry Into by Type (Therapeutics, Diagnostics), Biomarker Type (Genomic Biomarkers, Proteomic Biomarkers, and More), Cancer Type (Breast Cancer, Lung Cancer, and More), End-User (Hospitals & Cancer Centres, Diagnostic Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Precision Oncology Market Trends and Insights

Advancements in NGS & AI-Driven Analytics

AI now reduces whole-genome interpretation from days to hours, allowing real-time therapeutic decisions in acute leukemia and aggressive solid tumors. Illumina's DRAGEN platform is deployed at more than 1,200 clinical sites and processes a genome in under 90 minutes with high accuracy. FoundationOne CDx expanded into additional tumor types in early 2025 and integrates machine-learning models trained on more than 500,000 de-identified records, yielding a 78% positive predictive value for immunotherapy response. Oxford Nanopore's adaptive sampling further reduces the per-sample reagent cost by 40% while maintaining diagnostic sensitivity above 99%. These efficiency gains convert molecular profiling from an academic add-on into a routine decision-support tool across community oncology.

Rising Cancer Incidence & Favorable Reimbursement

New cancer cases reached 20.4 million globally in 2024, up 15% from 2020, an increase driven by aging populations and better detection in low- and middle-income nations. Medicare lifted prior-authorization hurdles and now pays up to USD 3,200 per comprehensive genomic profile, boosting test utilization by 60% in Q1 2025 alone. Germany, Japan, and the United Kingdom followed with similar reimbursement upgrades in 2025, sending a clear market signal that molecular information is now the standard of care. As a result, insurers worldwide are increasingly covering upfront profiling for lung, colorectal, and ovarian cancers, where actionable mutations have a prevalence exceeding 60%.

High Cost of Personalized Therapeutics & Testing

Targeted drugs, such as antibody-drug conjugates, regularly exceed USD 200,000 annually, far outstripping the health budget capacity in emerging economies. Comprehensive genomic profiling remains self-funded in India, Indonesia, and Brazil, where household income cannot absorb a USD 3,000 test. Even within high-income countries, payers demand real-world evidence proving cost-effectiveness at a level below USD 150,000 per quality-adjusted life year, which muddies coverage decisions for new therapies. Patent exclusivity on next-generation inhibitors delays biosimilar entry until after 2030, keeping drug prices elevated and curbing uptake.

Other drivers and restraints analyzed in the detailed report include:

1. Companion-Diagnostic Approvals Accelerating Commercialization
2. Rapid Adoption of Liquid Biopsy Platforms
3. Regulatory & Payer Uncertainties

For complete list of drivers and restraints, kindly check the Table Of Contents.

Geography Analysis

North America commanded 42.83% of the revenue in 2025, following the expansion of Medicare's genomic test coverage and the FDA's acceleration of companion diagnostic reviews. The region maintains leadership through widespread payer reimbursement and a dense sequencing infrastructure, yet its CAGR trails that of the Asia-Pacific region because penetration already exceeds 70% of eligible patients.

Asia-Pacific is forecast to post a 13.27% CAGR from 2026 to 2031, the fastest of any region, buoyed by China's 12 companion-diagnostic approvals in 2025 and provincial insurance that reimburses up to CNY 20,000 (USD 2,800) per comprehensive profile. BGI Genomics processed 800,000 oncology samples in 2025 and plans a 50% increase in capacity for 2026. Japan increased the payment for genomic profiling to JPY 800,000 (approximately USD 5,300), aligning with global benchmarks and encouraging domestic labs to adopt high-throughput sequencers.

Implementation of the In Vitro Diagnostic Regulation adds cost but harmonizes quality, ensuring reliable data across borders. Whole-genome sequencing within the U.K. Genomic Medicine Service doubled test volume in a year, and France launched regional molecular-tumor-board networks that mandate comprehensive profiling for advanced tumors.

South America and the Middle East & Africa together contribute less than 10% of the spend due to limited public coverage. Brazil cleared six companion diagnostics in 2025; however, without broad reimbursement, fewer than 20% of eligible patients receive the tests. South African private insurers now cover comprehensive genomic profiling, whereas government programs lag, leaving the majority excluded and limiting growth.

1. Adaptive Biotechnologies
2. Agendia NV
3. BGI
4. Burning Rock Biotech
5. Caris Life Sciences
6. Exact Sciences
7. Foundation Medicine Inc.
8. Roche
9. GRAIL LLC
10. Guardant Health
11. Illumina
12. LabCorp
13. Myriad Genetics
14. NanoString Technologies
15. Natera
16. NeoGenomics Laboratories
17. Novartis
18. Oxford Nanopore Technologies
19. Personalis Inc.
20. QIAGEN
21. Sophia Genetics
22. Strata Oncology Inc.
23. Tempus Labs Inc.
24. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Advancements in NGS & AI-Driven Analytics
  • 4.2.2 Rising Cancer Incidence & Favorable Reimbursement
  • 4.2.3 Companion-Diagnostic Approvals Accelerating Commercialisation
  • 4.2.4 Rapid Adoption of Liquid Biopsy Platforms
  • 4.2.5 Single-Cell Multi-Omics Integration
  • 4.2.6 Decentralised Clinical-Trial Models
• 4.3 Market Restraints
  • 4.3.1 High Cost of Personalised Therapeutics & Testing
  • 4.3.2 Regulatory & Payer Uncertainties
  • 4.3.3 Data-Privacy / Interoperability Barriers
  • 4.3.4 Genomic-Database Ethnic Skew
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Type
  • 5.1.1 Therapeutics
  • 5.1.2 Diagnostics
• 5.2 By Technology
  • 5.2.1 Next-Generation Sequencing (NGS)
  • 5.2.2 Polymerase Chain Reaction (PCR)
  • 5.2.3 Fluorescence In-Situ Hybridisation (FISH)
  • 5.2.4 Microarray
  • 5.2.5 Other Technologies
• 5.3 By Biomarker Type
  • 5.3.1 Genomic Biomarkers
  • 5.3.2 Proteomic Biomarkers
  • 5.3.3 Epigenomic Biomarkers
  • 5.3.4 Transcriptomic Biomarkers
  • 5.3.5 Metabolomic Biomarkers
• 5.4 By Cancer Type
  • 5.4.1 Breast Cancer
  • 5.4.2 Lung Cancer
  • 5.4.3 Colorectal Cancer
  • 5.4.4 Prostate Cancer
  • 5.4.5 Other Cancers
• 5.5 By End-User
  • 5.5.1 Hospitals & Cancer Centres
  • 5.5.2 Diagnostic Laboratories
  • 5.5.3 Pharma & Biotech Firms
  • 5.5.4 Research & Academic Institutes
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East & Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East & Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Adaptive Biotechnologies
  • 6.3.2 Agendia NV
  • 6.3.3 BGI Genomics
  • 6.3.4 Burning Rock Biotech
  • 6.3.5 Caris Life Sciences
  • 6.3.6 Exact Sciences Corporation
  • 6.3.7 Foundation Medicine Inc.
  • 6.3.8 F. Hoffmann-La Roche AG
  • 6.3.9 GRAIL LLC
  • 6.3.10 Guardant Health Inc.
  • 6.3.11 Illumina Inc.
  • 6.3.12 Labcorp
  • 6.3.13 Myriad Genetics Inc.
  • 6.3.14 NanoString Technologies
  • 6.3.15 Natera Inc.
  • 6.3.16 NeoGenomics Laboratories
  • 6.3.17 Novartis AG
  • 6.3.18 Oxford Nanopore Technologies
  • 6.3.19 Personalis Inc.
  • 6.3.20 QIAGEN NV
  • 6.3.21 Sophia Genetics
  • 6.3.22 Strata Oncology Inc.
  • 6.3.23 Tempus Labs Inc.
  • 6.3.24 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment